This page shows the latest rovalpituzumab tesirine news and features for those working in and with pharma, biotech and healthcare.
Rova-T (rovalpituzumab tesirine) consists of an anti-DLL3 antibody linked to a cancer-killing agent called pyrrolo-benzodiazepine.
The fate of its Rovalpituzumab Tesirine (Rova-T) also hangs in the balance after it failed in a phase 3 trial for small cell lung cancer in December.
The fall-off is no surprise given that AbbVie has spent the last few months building up expectations for antibody-drug conjugate Rova-T (rovalpituzumab tesirine), pointing to its blockbuster sales
The antibody drug conjugate (ADC) rovalpituzumab tesirine (Rova-T) achieved a modest improvement in a first-in-man trial in recurrent small cell lung cancer (SCLC), a disease with a notoriously
The acquisition will give AbbVie access to Stemcentrx's pipeline of five drugs in clinical trials, including a lead candidate called rovalpituzumab tesirine (rova-T) for small cell lung cancer (SCLC)
More from news
Approximately 1 fully matching, plus 4 partially matching documents found.
Its lead compound, Rovalpituzumab tesirine (Rova-T), is a biomarker-specific antibody drug conjugate, in phase I/II targeting cancer stem cell protein DLL3.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...